Cuadros, MartaAndrades, AlvaroCoira, Isabel FBaliñas, CarlosRodriguez, Maria IAlvarez-Perez, Juan CarlosPeinado, PaolaArenas, Alberto MGarcia, Daniel JJimenez, PilarCamos, MireiaJimenez-Velasco, AntonioMedina, Pedro P2023-02-082023-02-082019-11-25Cuadros M, Andrades Á, Coira IF, Baliñas C, Rodríguez MI, Álvarez-Pérez JC, et al. Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia. Blood Cancer J. 2019 Nov 25;9(12):93http://hdl.handle.net/10668/14742Acute lymphoblastic leukemia (ALL) is a clinically and biologically heterogeneous disease recurrently affected by chromosomal aberrations, including translocations, amplifications, and aneuploidies1. These aberrations have important implications for the diagnosis, sub-classification, prognosis and, overall, for making appropriate therapeutic decisions. The reciprocal translocation t(12;21)(p13;q22)[ETV6/RUNX1] is the most frequent chromosomal rearrangement in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with an incidence of ~25%2. This rearrangement, as well as high hyperdiploidy, is associated with a favorable outcome under current treatment protocols, but up to 20% of ETV6-RUNX1positive pediatric B-ALL patients experience a late disease relapse1,3.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Biomarkers, TumorCore Binding Factor Alpha 2 SubunitGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrognosisRNA InterferenceRNA, Long Noncodingresearch article31767830open accessLeucemia-linfoma linfoblástico de células precursorasAberraciones cromosómicasProtocolos clínicosCélulasClasificación10.1038/s41408-019-0258-92044-5385PMC6877621https://www.nature.com/articles/s41408-019-0258-9.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877621/pdf